welcome
Reuters

Reuters

Health

Health

Eli Lilly forecasts weaker Q4 sales of weight-loss drug, Mounjaro than expected

Reuters
Summary
Nutrition label

78% Informative

Eli Lilly expects sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street expectations in the fourth quarter .

Lilly said it expects 2025 sales between $58 billion and $61 billion .

Analysts were expecting revenue of $58.52 billion .

VR Score

89

Informative language

98

Neutral language

23

Article tone

formal

Language

English

Language complexity

49

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links

Small business owner?

Otherweb launches Autoblogger—a revolutionary way to bring more leads to any small business, using the power of AI.